{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:23:28Z","timestamp":1791944608534,"version":"4.3.4"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"crossref","award":["2021\/14151-7"],"award-info":[{"award-number":["2021\/14151-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"crossref","award":["2021\/14151-7"],"award-info":[{"award-number":["2021\/14151-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11102-025-01541-0","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T17:09:10Z","timestamp":1748884150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4774-4093","authenticated-orcid":false,"given":"Ana Beatriz Ribeiro","family":"Cardoso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1226-556X","authenticated-orcid":false,"given":"Amanda Cristina","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9517-338X","authenticated-orcid":false,"given":"Gerald","family":"Raverot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9316-4167","authenticated-orcid":false,"given":"Vania dos Santos","family":"Nunes-Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"issue":"3","key":"1541_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JAH (2010) Prevalence of pituitary adenomas: a community-based, cross\u2010sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 72(3):377\u2013382","journal-title":"Clin Endocrinol"},{"issue":"5","key":"1541_CR2","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1210\/jc.2004-2231","volume":"90","author":"GA Kaltsas","year":"2005","unstructured":"Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metabolism 90(5):3089\u20133099","journal-title":"J Clin Endocrinol Metabolism"},{"key":"1541_CR3","doi-asserted-by":"crossref","unstructured":"McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, Burman P (2016) Treatment of aggressive pituitary tumours and carcinomas: Results of a European Society of Endocrinology (ESE) survey. 2018","DOI":"10.1530\/endoabs.49.OC12.2"},{"issue":"11","key":"1541_CR4","doi-asserted-by":"publisher","first-page":"R559","DOI":"10.1530\/ERC-18-0228","volume":"25","author":"D Dworakowska","year":"2018","unstructured":"Dworakowska D, Grossman AB (2018) Aggressive and malignant pituitary tumours: state-of-the-art. Endocrine-related Cancer 25(11):R559\u2013R575","journal-title":"Endocrine-related Cancer"},{"issue":"1","key":"1541_CR5","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, Trouillas J, Dekkers OM (2018) European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178(1):G1\u2013G24","journal-title":"Eur J Endocrinol"},{"issue":"20","key":"1541_CR6","first-page":"1537","volume":"98","author":"XH Liu","year":"2018","unstructured":"Liu XH, Wang RZ, Dai CX (2018) [Clinical significance of European society of endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas]. Zhonghua Yi Xue Za Zhi 98(20):1537\u20131539","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"1","key":"1541_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","volume":"15","author":"MH Kulke","year":"2009","unstructured":"Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS (2009) O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15(1):338\u2013345","journal-title":"Clin Cancer Res"},{"key":"1541_CR8","doi-asserted-by":"publisher","first-page":"216908","DOI":"10.1016\/j.canlet.2024.216908","volume":"592","author":"X Guo","year":"2024","unstructured":"Guo X, Yang Y, Qian Z, Chang M, Zhao Y, Ma W, Wang Y, Xing B (2024) Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors. Cancer Lett 592:216908","journal-title":"Cancer Lett"},{"issue":"5","key":"1541_CR9","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1530\/EC-19-0065","volume":"8","author":"G Giuffrida","year":"2019","unstructured":"Giuffrida G, Ferra\u00f9 F, Laudicella R, Cotta OR, Messina E, Granata F, Angileri FF, Vento A, Alibrandi A, Baldari S, Cannav\u00f2 S (2019) Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience. Endocr Connections 8(5):528\u2013535","journal-title":"Endocr Connections"},{"issue":"3","key":"1541_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1055\/a-1260-3975","volume":"129","author":"K Osterhage","year":"2021","unstructured":"Osterhage K, Rotermund R, Droste M, Dierlamm J, Saeger W, Petersenn S, Aberle J, Flitsch J (2021) Bevacizumab in aggressive pituitary Adenomas-Experience with 3 patients. Experimental Clin Endocrinol Diabetes 129(3):178\u2013185","journal-title":"Experimental Clin Endocrinol Diabetes"},{"issue":"7","key":"1541_CR11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/modpathol.3800118","volume":"17","author":"O Onguru","year":"2004","unstructured":"Onguru O, Scheithauer BW, Kovacs K, Vidal S, Jin L, Zhang S, Ruebel KH, Lloyd RV (2004) Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas. Mod Pathol 17(7):772\u2013780","journal-title":"Mod Pathol"},{"issue":"4","key":"1541_CR12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1677\/ERC-09-0101","volume":"16","author":"D Dworakowska","year":"2009","unstructured":"Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, G\u00f3th MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M, Grossman AB (2009) Activation of RAF\/MEK\/ERK and PI3K\/AKT\/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocrine-related Cancer 16(4):1329\u20131338","journal-title":"Endocrine-related Cancer"},{"issue":"8","key":"1541_CR13","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1080\/14656566.2018.1476492","volume":"19","author":"L Lee","year":"2018","unstructured":"Lee L, Ito T, Jensen RT (2018) Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 19(8):909\u2013928","journal-title":"Expert Opin Pharmacother"},{"key":"1541_CR14","doi-asserted-by":"publisher","first-page":"700007","DOI":"10.3389\/fneur.2021.700007","volume":"12","author":"M Luo","year":"2021","unstructured":"Luo M, Tan Y, Chen W, Hu B, Wang Z, Zhu D, Jiao H, Duan C, Zhu Y, Wang H (2021) Clinical efficacy of Temozolomide and its predictors in aggressive pituitary tumors and pituitary carcinomas: A systematic review and Meta-Analysis. Front Neurol 12:700007","journal-title":"Front Neurol"},{"key":"1541_CR15","doi-asserted-by":"publisher","first-page":"108506","DOI":"10.1016\/j.pharmthera.2023.108506","volume":"250","author":"MD Ilie","year":"2023","unstructured":"Ilie MD, De Alcubierre D, Carretti AL, Jouanneau E, Raverot G (2023) Therapeutic targeting of the pituitary tumor microenvironment. Pharmacol Ther 250:108506","journal-title":"Pharmacol Ther"},{"issue":"3","key":"1541_CR16","first-page":"321","volume":"49","author":"DDEA Carretti","year":"2024","unstructured":"Carretti DDEA, Ducray AL, Jouanneau F, Raverot E, Ilie G MD (2024) Aggressive pituitary tumors and carcinomas: medical treatment beyond Temozolomide. Minerva Endocrinol (Torino) 49(3):321\u2013334","journal-title":"Minerva Endocrinol (Torino)"},{"issue":"3","key":"1541_CR17","first-page":"188","volume":"3","author":"Y Ji","year":"2016","unstructured":"Ji Y, Vogel RI, Lou E (2016) Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports. Neurooncol Pract 3(3):188\u2013195","journal-title":"Neurooncol Pract"},{"key":"1541_CR18","doi-asserted-by":"crossref","unstructured":"Tufanaru (2020) Chapter 3: systematic reviews of effectiveness. JBI, JBI Manual for Evidence Synthesis","DOI":"10.46658\/JBIRM-17-03"},{"key":"1541_CR19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"2","key":"1541_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"1","key":"1541_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5(1):210","journal-title":"Syst Rev"},{"issue":"10","key":"1541_CR22","first-page":"2127","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, Stephenson M, Aromataris E (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 18(10):2127\u20132133","journal-title":"JBI Evid Synth"},{"issue":"1","key":"1541_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/2049-3258-72-39","volume":"72","author":"VN Nyaga","year":"2014","unstructured":"Nyaga VN, Arbyn M, Aerts M (2014) Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 72(1):39","journal-title":"Arch Public Health"},{"key":"1541_CR24","doi-asserted-by":"crossref","unstructured":"Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (2019) Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons","DOI":"10.1002\/9781119536604"},{"issue":"12","key":"1541_CR25","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, Atkins D, Kunz R, Brozek J, Montori V, Jaeschke R, Rind D, Dahm P, Meerpohl J, Vist G, Berliner E, Norris S, Falck-Ytter Y, Murad MH, Sch\u00fcnemann HJ (2011) GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 64(12):1311\u20131316","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"1541_CR26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1530\/EJE-22-0440","volume":"187","author":"P Burman","year":"2022","unstructured":"Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, Popovic V, Theodoropoulou M, Raverot G, Dekkers OM, Guenego A, Micko A, Hubalewska-Dydejezky A, Troendle A, McCormack A, Krogh Rasmussen \u00c5, Whitelaw B, Decoudier B, Ekman B, Engstr\u00f6m BE, H\u00f6ybye C, Jublanc C, Cortet Rudelli C, Higham C, Garcia C, Bresson D, Henley D, Larrieu-Ciron D, Maiter D, Laws ER, Christ E, Kuhn E, Ceccato F, Schillo F, Castinetti F, Raverot G, Mantovani G, Vila G, Lasolle H, Garay IB, Kralievic I, Otto Lunde Jorgensen J, Berinder K, Ritzel K, Bach L, Ortiz LD, Criniere L, Syro L, Haissaguerre M, Losa M, Zatelli MC, Batisse-Lignier M, Jaffrain-Rea M-L, Korbonits M, Ragonese M, Reincke M, Toth M, Bourcigaux N, Chevalier N, Ragnarsson O, Chanson P, Burman P, Pekic S, Petersenn S, Mallea-Gil S, Usui T, Deutschbein T, Mazzuco TL, Dusek T, Feldt-Rasmussen U, Popovic V, Greenman Y (2022) Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol 187(4):593\u2013605","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1541_CR27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s11102-011-0363-7","volume":"15","author":"AK Annamalai","year":"2012","unstructured":"Annamalai AK, Dean AF, Kandasamy N, Kovacs K, Burton H, Halsall DJ, Shaw AS, Antoun NM, Cheow HK, Kirollos RW, Pickard JD, Simpson HL, Jefferies SJ, Burnet NG, Gurnell M (2012) Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature. Pituitary 15(3):276\u2013287","journal-title":"Pituitary"},{"issue":"4","key":"1541_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21926\/obm.neurobiol.1804014","volume":"2","author":"B Mella","year":"2018","unstructured":"Mella B, Sewell D, Pan J E (2018) A case series of Temozolomide in the management of refractory prolactinomas. OBM Neurobiol 2(4):1\u20131","journal-title":"OBM Neurobiol"},{"key":"1541_CR29","unstructured":"Baldauf MJWLAHTBM (2022) Case report: response of corticotroph adenoma to Temozolomide in a patient with Nelson syndrome. European Journal of Neurology"},{"key":"1541_CR30","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.wneu.2018.07.082","volume":"118","author":"G Barkhoudarian","year":"2018","unstructured":"Barkhoudarian G, Palejwala SK, Ogunbameru R, Wei H, Eisenberg A, Kelly DF (2018) Early recognition and initiation of Temozolomide chemotherapy for refractory, invasive pituitary macroprolactinoma with Long-Term sustained remission. World Neurosurg 118:118\u2013124","journal-title":"World Neurosurg"},{"issue":"4","key":"1541_CR31","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1210\/jc.2014-4350","volume":"100","author":"D Bengtsson","year":"2015","unstructured":"Bengtsson D, Schr\u00f8der HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, Rasmussen \u00c5K, Johannsson G, Hoybye C, van der Lely AJ, Petersson M, Ragnarsson O, Burman P (2015) Long-Term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with Temozolomide. J Clin Endocrinol Metabolism 100(4):1689\u20131698","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"10","key":"1541_CR32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.endinu.2017.08.007","volume":"64","author":"I Bilbao","year":"2017","unstructured":"Bilbao I, Ega\u00f1a N, Garc\u00eda C, Olaizola I (2017) Fracaso de Un Segundo Ciclo de Tratamiento Con temozolamida En Un Paciente afectado de carcinoma Hipofisario productor de prolactina. Endocrinolog\u00eda Diabetes Y Nutrici\u00f3n 64(10):564\u2013566","journal-title":"Endocrinolog\u00eda Diabetes Y Nutrici\u00f3n"},{"issue":"1","key":"1541_CR33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13256-022-03390-y","volume":"16","author":"MK Borhan","year":"2022","unstructured":"Borhan MK, Tan FHS (2022) Aggressive giant prolactinoma: a case report. J Med Case Rep 16(1):170\u2013170","journal-title":"J Med Case Rep"},{"key":"1541_CR34","doi-asserted-by":"crossref","unstructured":"Bruno OD, Ju\u00e1rez-Allen L, Christiansen SB, Manavela M, Danilowicz K, Vigovich C, G\u00f3mez RM (2015) Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina. International Journal of Endocrinology 2015:1\u20138","DOI":"10.1155\/2015\/587893"},{"issue":"11","key":"1541_CR35","doi-asserted-by":"publisher","first-page":"E280","DOI":"10.1210\/jc.2010-0441","volume":"95","author":"ZM Bush","year":"2010","unstructured":"Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA, Vance ML, Thorner MO, Laws ER, Lopes MBS (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with o\u2009<\u2009sup\u2009>\u20096 -Methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metabolism 95(11):E280\u2013E290","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"12","key":"1541_CR36","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.jocn.2009.05.013","volume":"16","author":"S Byrne","year":"2009","unstructured":"Byrne S, Karapetis C, Vrodos N (2009) A novel use of Temozolomide in a patient with malignant prolactinoma. J Clin Neurosci 16(12):1694\u20131696","journal-title":"J Clin Neurosci"},{"issue":"47","key":"1541_CR37","doi-asserted-by":"publisher","first-page":"e8733","DOI":"10.1097\/MD.0000000000008733","volume":"96","author":"C Chen","year":"2017","unstructured":"Chen C, Yin S, Zhang S, Wang M, Hu Y, Zhou P, Jiang S (2017) Treatment of aggressive prolactinoma with Temozolomide. Medicine 96(47):e8733\u2013e8733","journal-title":"Medicine"},{"key":"1541_CR38","unstructured":"Cozzi Rlglscmfgsacamaar (2011) Temozolomide in three patients with pituitary adenoma. Endocrine Reviews"},{"key":"1541_CR39","doi-asserted-by":"crossref","unstructured":"Das L, Rai A, Salunke P, Ahuja CK, Sood A, Radotra BD, Sood R, Korbonits M, Dutta P (2022) Temozolomide nonresponsiveness in aggressive prolactinomas and carcinomas: management and outcomes. J Endocr Soc 6(2)","DOI":"10.1210\/jendso\/bvab190"},{"key":"1541_CR40","doi-asserted-by":"crossref","unstructured":"Decaroli MC, Ansaloni A, Monzani ML, Losa M, Zunarelli E, Rochira V, Madeo B (2021) Long-Term use of Temozolomide as safe and effective therapy for an aggressive corticotroph adenoma in a very old patient. J Endocr Soc 5(8)","DOI":"10.1210\/jendso\/bvab065"},{"issue":"1","key":"1541_CR41","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11102-010-0264-1","volume":"14","author":"TH Dillard","year":"2011","unstructured":"Dillard TH, Gultekin SH, Delashaw JB, Yedinak CG, Neuwelt EA, Fleseriu M (2011) Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary 14(1):80\u201391","journal-title":"Pituitary"},{"issue":"Supplement6","key":"1541_CR42","first-page":"vi83","volume":"23","author":"K Duncan","year":"2021","unstructured":"Duncan K, Arafah B, Rogers L (2021) DDRE-41. Treatment of refractory pituitary neoplasms with temozolomide in three patients. Neurooncology 23(Supplement6):vi83\u2013vi83","journal-title":"Neurooncology"},{"issue":"3","key":"1541_CR43","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1210\/clinem\/dgz211","volume":"105","author":"U Elbelt","year":"2020","unstructured":"Elbelt U, Schlaffer SM, Buchfelder M, Knappe UJ, Vila G, Micko A, Deutschbein T, Unger N, Lammert A, Topuzoglu-M\u00fcller T, Bojunga J, Droste M, Johanssen S, Kolenda H, Ritzel K, Buslei R, Strasburger CJ, Petersenn S, Honegger J (2020) Efficacy of Temozolomide therapy in patients with aggressive pituitary adenomas and Carcinomas\u2014A German survey. J Clin Endocrinol Metabolism 105(3):e660\u2013e675","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"4","key":"1541_CR44","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3171\/jns.2006.105.4.621","volume":"105","author":"CE Fadul","year":"2006","unstructured":"Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE (2006) Long-term response of pituitary carcinoma to Temozolomide. J Neurosurg 105(4):621\u2013626","journal-title":"J Neurosurg"},{"key":"1541_CR45","doi-asserted-by":"crossref","unstructured":"Felker J, Patterson B, Wrubel D, Janss A (2016) Successful treatment of a child with a prolactin secreting Macroadenoma with Temozolomide. J Pediatr Endocrinol Metab 29(12)","DOI":"10.1515\/jpem-2016-0159"},{"issue":"2","key":"1541_CR46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12022-015-9361-z","volume":"26","author":"AA Ghazi","year":"2015","unstructured":"Ghazi AA, Rotondo F, Kovacs K, Amirbaigloo A, Syro LV, Fathalla H, Di Ieva A, Cusimano MD (2015) Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature. Endocr Pathol 26(2):135\u2013139","journal-title":"Endocr Pathol"},{"key":"1541_CR47","doi-asserted-by":"crossref","unstructured":"Gilis-Januszewska A, Wilusz M, Pantofli\u0144ski J, Turek-Jabrocka R, Soko\u0142owski G, Sowa-Staszczak A, Kluczy\u0144ski \u0141, Pach D, Zieli\u0144ski G, Hubalewska-Dydejczyk A (2015) Temozolomide therapy for aggressive pituitary Crooke\u2019s cells corticotropinoma causing Cushing\u2019s disease: A case report with literature review. Endokrynologia Polska","DOI":"10.5603\/EP.a2018.0011"},{"issue":"12","key":"1541_CR48","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1177\/0883073808319078","volume":"23","author":"A Guzel","year":"2008","unstructured":"Guzel A, Tatli M, Senturk S, Guzel E, Cayli RS, Sav A (2008) Pituitary carcinoma presenting with multiple metastases: case report. J Child Neurol 23(12):1467\u20131471","journal-title":"J Child Neurol"},{"issue":"4","key":"1541_CR49","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-09-0389","volume":"161","author":"C Hagen","year":"2009","unstructured":"Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M (2009) Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol 161(4):631\u2013637","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1541_CR50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.humpath.2006.07.014","volume":"38","author":"K Kovacs","year":"2007","unstructured":"Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE (2007) Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 38(1):185\u2013189","journal-title":"Hum Pathol"},{"key":"1541_CR51","doi-asserted-by":"crossref","unstructured":"Kurowska M, Nowakowski A, Zieli\u0144ski G, Malicka J, Tarach JS, Maksymowicz M, Denew P (2015) Temozolomide-Induced Shrinkage of Invasive Pituitary Adenoma in Patient with Nelson\u2019s Syndrome: A Case Report and Review of the Literature. Case Reports in Endocrinology 2015:1\u20138","DOI":"10.1155\/2015\/623092"},{"issue":"5","key":"1541_CR52","doi-asserted-by":"publisher","first-page":"526","DOI":"10.5603\/EP.2016.0060","volume":"67","author":"M Kurowska","year":"2016","unstructured":"Kurowska M, Tarach JS, Malicka J, Zieli\u0144ski G, Maksymowicz M, Denew P (2016) D\u0142ugotrwa\u0142a Ca\u0142kowita Remisja Guza Kortykotropowego Z Kom\u00f3rek Crooke\u2019a Po Leczeniu temozolomidem. Endokrynologia Polska 67(5):526\u2013533","journal-title":"Endokrynologia Polska"},{"issue":"4","key":"1541_CR53","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11102-020-01040-4","volume":"23","author":"L Lizzul","year":"2020","unstructured":"Lizzul L, Lombardi G, Barbot M, Ceccato F, Gardiman MP, Regazzo D, Bellu L, Mazza E, Losa M, Scaroni C (2020) Long-course Temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. Pituitary 23(4):359\u2013366","journal-title":"Pituitary"},{"issue":"3","key":"1541_CR54","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11060-015-1991-y","volume":"126","author":"M Losa","year":"2016","unstructured":"Losa M, Bogazzi F, Cannavo S, Ceccato F, Curt\u00f2 L, De Marinis L, Iacovazzo D, Lombardi G, Mantovani G, Mazza E, Minniti G, Nizzoli M, Reni M, Scaroni C (2016) Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. J Neurooncol 126(3):519\u2013525","journal-title":"J Neurooncol"},{"issue":"2","key":"1541_CR55","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1365-2265.2008.03487.x","volume":"71","author":"AI McCormack","year":"2009","unstructured":"McCormack AI, McDonald KL, Gill AJ, Clark SJ, Burt MG, Campbell KA, Braund WJ, Little NS, Cook RJ, Grossman AB, Robinson BG, Clifton-Bligh RJ (2009) Low o\u2009<\u2009sup\u2009>\u20096 \u2010methylguanine\u2010DNA methyltransferase (MGMT) expression and response to Temozolomide in aggressive pituitary tumours. Clin Endocrinol 71(2):226\u2013233","journal-title":"Clin Endocrinol"},{"issue":"8","key":"1541_CR56","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1210\/jc.2014-1183","volume":"99","author":"M Mendola","year":"2014","unstructured":"Mendola M, Passeri E, Ambrosi B, Corbetta S (2014) Multiple cerebral hemorrhagic foci from metastases during Temozolomide treatment in a patient with corticotroph pituitary carcinoma. J Clin Endocrinol Metabolism 99(8):2623\u20132624","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"4","key":"1541_CR57","doi-asserted-by":"publisher","first-page":"E773","DOI":"10.1227\/01.NEU.0000339115.12803.4E","volume":"64","author":"S Mohammed","year":"2009","unstructured":"Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD (2009) Use of temozolomide in aggressive pituitary tumors. Neurosurgery 64(4):E773\u2013E774","journal-title":"Neurosurgery"},{"issue":"1","key":"1541_CR58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11102-010-0232-9","volume":"15","author":"E Morin","year":"2012","unstructured":"Morin E, Berthelet F, Weisnagel J, Bidlingmaier M, Serri O (2012) Failure of Temozolomide and conventional doses of Pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary 15(1):97\u2013100","journal-title":"Pituitary"},{"issue":"2","key":"1541_CR59","doi-asserted-by":"publisher","first-page":"162","DOI":"10.14310\/horm.2002.1307","volume":"10","author":"O Moshkin","year":"2011","unstructured":"Moshkin O, Syro L, Scheithauer B, Ortiz L, Fadul C, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K (2011) Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of Temozolomide therapy. HORMONES 10(2):162\u2013167","journal-title":"HORMONES"},{"issue":"6","key":"1541_CR60","doi-asserted-by":"publisher","first-page":"E1761","DOI":"10.1227\/NEU.0b013e318217161a","volume":"68","author":"M Murakami","year":"2011","unstructured":"Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K, Ishida Y, Takano K, Okinaga H, Matsuno A (2011) A mechanism of acquiring Temozolomide resistance during transformation of atypical prolactinoma into Prolactin-Producing pituitary carcinoma: case report. Neurosurgery 68(6):E1761\u2013E1767","journal-title":"Neurosurgery"},{"issue":"1","key":"1541_CR61","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s11102-007-0014-1","volume":"10","author":"LM Neff","year":"2007","unstructured":"Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu J-J, Tischler AS, Lechan RM (2007) Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10(1):81\u201386","journal-title":"Pituitary"},{"issue":"6","key":"1541_CR62","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.4158\/EP12400.CR","volume":"19","author":"LV Neto","year":"2013","unstructured":"Neto LV, Chimelli L, Pereira PJM, Gasparetto EL, Bines J, Wildemberg LEA, Gadelha MR (2013) The role of Temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma. Endocr Pract 19(6):e145\u2013e149","journal-title":"Endocr Pract"},{"key":"1541_CR63","doi-asserted-by":"crossref","unstructured":"Park JY, Choi W, Ram Hong A, Yoon JH, Kim Hk, Kang H-C (2023) THU018 remarkable response of ACTH-secreting pituitary carcinoma to immune checkpoint inhibitors: A Case Report. J Endocr Soc. 2023;7(Suppl 1):bvad114.1099.","DOI":"10.1210\/jendso\/bvad114.1099"},{"issue":"3","key":"1541_CR64","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ando.2012.03.001","volume":"73","author":"M Philippon","year":"2012","unstructured":"Philippon M, Morange I, Barrie M, Barlier A, Taieb D, Dufour H, Conte-Devolx B, Brue T, Castinetti F (2012) Long-term control of a MEN1 prolactin secreting pituitary carcinoma after Temozolomide treatment. Ann Endocrinol 73(3):225\u2013229","journal-title":"Ann Endocrinol"},{"key":"1541_CR65","doi-asserted-by":"crossref","unstructured":"Prickett J, Altafulla J, Knisely A, Benkers T, Litvack Z (eds) Recurrent Corticotropic Pituitary Adenoma Treated Successfully with Temozolomide: A Case Report2019 2019\/2\/\/","DOI":"10.1055\/s-0039-1679687"},{"key":"1541_CR66","unstructured":"Rajeev S, P SCBSHDBADKGCDC (2015) Temozolomide in the management of aggressive, somatotroph pituitary adenomas-a single centre experience from the United Kingdom. Endocrine Reviews"},{"key":"1541_CR67","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.wneu.2018.11.011","volume":"122","author":"LE Rotman","year":"2019","unstructured":"Rotman LE, Vaughan TB, Hackney JR, Riley KO (2019) Long-Term survival after transformation of an adrenocorticotropic Hormone\u2013Secreting pituitary Macroadenoma to a silent corticotroph pituitary carcinoma. World Neurosurg 122:417\u2013423","journal-title":"World Neurosurg"},{"key":"1541_CR68","doi-asserted-by":"crossref","unstructured":"Steele C, Roncaroli F, Baborie A, Syed N, Husband D, Das KSV, Javadpour M, Macfarlane I, Daousi C (2011) Aggressive Sparsely Granulated Somatotroph Adenoma of the Pituitary Responding Favorably to Temozolomide. p. OR36-36","DOI":"10.1210\/endo-meetings.2011.PART4.OR8.OR36-6"},{"key":"1541_CR69","doi-asserted-by":"crossref","unstructured":"Stelmachowska-Bana\u015b M, Maksymowicz M, Kolasi\u0144ska-\u0106wik\u0142a A, Zieli\u0144ski G, Korbonits M, Zgliczy\u0144ski W (2021) Pituitary carcinoma as a rare cause of liver metastases successfully treated with Temozolomide. Polish Archives of Internal Medicine","DOI":"10.20452\/pamw.16178"},{"issue":"3","key":"1541_CR70","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1177\/1078155215569556","volume":"22","author":"RE Strowd","year":"2016","unstructured":"Strowd RE, Salvatori R, Laterra JJ (2016) Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: hormonal and radiographic response. J Oncol Pharm Pract 22(3):517\u2013522","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"1541_CR71","doi-asserted-by":"publisher","first-page":"303","DOI":"10.14310\/horm.2002.1247","volume":"8","author":"L Syro","year":"2009","unstructured":"Syro L, Scheithauer B, Ortiz L, Fadul C, Horvath E, Rotondo F, Kovacs K (2009) Effect of Temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. HORMONES 8(4):303\u2013306","journal-title":"HORMONES"},{"key":"1541_CR72","doi-asserted-by":"crossref","unstructured":"Tang H, Cheng Y, Huang J, Li J, Zhang B, Wu ZB (2021) Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists. Frontiers in Endocrinology 12","DOI":"10.3389\/fendo.2021.616339"},{"issue":"10","key":"1541_CR73","first-page":"451","volume":"75","author":"A van der Vlist","year":"2017","unstructured":"van der Vlist A, Snijders TJ, Stades AME, Spliet WGM, De Vos FYFL (2017) Successful treatment of leptomeningeally metastasised pituitary carcinoma with Temozolomide. Neth J Med 75(10):451\u2013454","journal-title":"Neth J Med"},{"issue":"6","key":"1541_CR74","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/j.1365-2265.2012.04373.x","volume":"76","author":"BC Whitelaw","year":"2012","unstructured":"Whitelaw BC, Dworakowska D, Thomas NW, Barazi S, Riordan-Eva P, King AP, Hampton T, Landau DB, Lipscomb D, Buchanan CR, Gilbert JA, Aylwin SJB (2012) Temozolomide in the management of dopamine agonist\u2013resistant prolactinomas. Clin Endocrinol 76(6):877\u2013886","journal-title":"Clin Endocrinol"},{"key":"1541_CR75","doi-asserted-by":"crossref","unstructured":"Zampetti B, Simonetti G, Attanasio R, Silvani A, Cozzi R (2018) Effective long-term temozolomide rechallenge in a macroprolactinoma. Endocrinology, Diabetes & Metabolism Case Reports 2018","DOI":"10.1530\/EDM-18-0092"},{"key":"1541_CR76","doi-asserted-by":"crossref","unstructured":"Ishida A, Shichi H, Fukuoka H, Shiramizu H, Inoshita N, Yamada S (2022) Temozolomide and Capecitabine Treatment for an Aggressive Somatotroph Pituitary Tumor: A Case Report and Literature Review. Frontiers in Oncology 12","DOI":"10.3389\/fonc.2022.916982"},{"issue":"4","key":"1541_CR77","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s11102-009-0211-1","volume":"14","author":"MS Thearle","year":"2011","unstructured":"Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y, Fine RL (2011) Temozolomide (Temodar\u00ae) and capecitabine (Xeloda\u00ae) treatment of an aggressive corticotroph pituitary tumor. Pituitary 14(4):418\u2013424","journal-title":"Pituitary"},{"key":"1541_CR78","unstructured":"Yang JW, Dotan I, Owen S, Posner BI, Garfield N (eds) (2017) A rare case of metastatic prolactinoma:; 2017; Orlando, FL, United States"},{"key":"1541_CR79","doi-asserted-by":"crossref","unstructured":"Mirallas O, Filippi-Arriaga F, Hernandez Hernandez I, Aubanell A, Chaachou A, Garcia-Alvarez A, Hernando J, Mart\u00ednez-Saez E, Biagetti B, Capdevila J (2021) Aggressive pituitary Macroadenoma treated with capecitabine and Temozolomide chemotherapy combination in a patient with Nelson\u2019s syndrome: A case report. Frontiers in Endocrinology 12.","DOI":"10.3389\/fendo.2021.731631"},{"key":"1541_CR80","unstructured":"Page-Wilson GWSLFPUBJNFRL (ed) (2013) Capecitabine and Temozolomide (CAPTEM)for the treatment of refractory cushing\u2019sdisease (CD) Secondary to an aggressiveACTH-secreting Pituitary Tumor. San Francisco, CA, United States"},{"key":"1541_CR81","doi-asserted-by":"crossref","unstructured":"Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, Siegelin M, Remotti H, Lignelli A, Fine RL (2014) High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and Temozolomide (CAPTEM): A case series. Neurosurgery 74(4)","DOI":"10.1227\/NEU.0000000000000251"},{"key":"1541_CR82","doi-asserted-by":"crossref","unstructured":"Majd N, Waguespack SG, Janku F, Fu S, Penas-Prado M, Xu M, Alshawa A, Kamiya-Matsuoka C, Raza SM, McCutcheon IE, Naing A (2020) Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. J Immunother Cancer 8(2)","DOI":"10.1136\/jitc-2020-001532"},{"issue":"2","key":"1541_CR83","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/CAD.0000000000000856","volume":"31","author":"M Caccese","year":"2020","unstructured":"Caccese M, Barbot M, Ceccato F, Padovan M, Gardiman MP, Fassan M, Denaro L, Emanuelli E, D\u2019Avella D, Scaroni C, Zagonel V, Lombardi G (2020) Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab. Anticancer Drugs 31(2):199\u2013204","journal-title":"Anticancer Drugs"},{"issue":"3","key":"1541_CR84","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1053\/j.seminoncol.2018.06.001","volume":"45","author":"RT Casey","year":"2018","unstructured":"Casey RT, Giger O, Seetho I, Marker A, Pitfield D, Boyle LH, Gurnell M, Shaw A, Tischkowitz M, Maher ER, Chatterjee VK, Janowitz T, Mells G, Corrie P, Challis BG (2018) Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab. Semin Oncol 45(3):151\u2013155","journal-title":"Semin Oncol"},{"issue":"5","key":"1541_CR85","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1530\/EJE-22-0647","volume":"187","author":"MD Ilie","year":"2022","unstructured":"Ilie MD, Villa C, Cuny T, Cortet C, Assie G, Baussart B, Cancel M, Chanson P, Decoudier B, Deluche E, Di Stefano AL, Drui D, Gaillard S, Goichot B, Huillard O, Joncour A, Larrieu-Ciron D, Libe R, Nars G, Vasiljevic A, Raverot G (2022) Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study. Eur J Endocrinol 187(5):685\u2013696","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"1541_CR86","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1210\/jc.2018-01347","volume":"103","author":"AL Lin","year":"2018","unstructured":"Lin AL, Jonsson P, Tabar V, Yang TJ, Cuaron J, Beal K, Cohen M, Postow M, Rosenblum M, Shia J, Deangelis LM, Taylor BS, Young RJ, Geer EB (2018) Marked response of a hypermutated acth-secreting pituitary carcinoma to ipilimumab and nivolumab. J Clin Endocrinol Metab 103(10):3925\u20133930","journal-title":"J Clin Endocrinol Metab"},{"key":"1541_CR87","doi-asserted-by":"crossref","unstructured":"Lamb LS, Sim H-W, McCormack AI (2020) Case report: A case of pituitary carcinoma treated with sequential dual immunotherapy and vascular endothelial growth factor Inhibition therapy. Frontiers in Endocrinology 11.","DOI":"10.3389\/fendo.2020.576027"},{"issue":"2","key":"1541_CR88","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1227\/neu.0000000000002024","volume":"91","author":"S Shah","year":"2022","unstructured":"Shah S, Manzoor S, Rothman Y, Hagen M, Pater L, Golnik K, Mahammedi A, Lin AL, Bhabhra R, Forbes JA, Sengupta S (2022) Complete response of a patient with a mismatch repair deficient aggressive pituitary adenoma to immune checkpoint inhibitor therapy: A case report. Neurosurgery 91(2):e51\u2013e56","journal-title":"Neurosurgery"},{"issue":"1","key":"1541_CR89","doi-asserted-by":"publisher","first-page":"K1","DOI":"10.1530\/EJE-20-0151","volume":"184","author":"B Sol","year":"2021","unstructured":"Sol B, de Filette JMK, Awada G, Raeymaeckers S, Aspeslagh S, Andreescu CE, Neyns B, Velkeniers B (2021) Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment? Eur J Endocrinol 184(1):K1\u2013K5","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1541_CR90","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s00259-019-04578-z","volume":"47","author":"M Assadi","year":"2020","unstructured":"Assadi M, Nemati R, Shooli H, Rekabpour SJ, Nabipour I, Jafari E, Gholamrezanezhad A, Amini A, Ahmadzadehfar H (2020) An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 47(4):1015\u20131016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"S1","key":"1541_CR91","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11102-011-0373-5","volume":"15","author":"S Baldari","year":"2012","unstructured":"Baldari S, Ferra\u00f9 F, Alafaci C, Herberg A, Granata F, Militano V, Salpietro FM, Trimarchi F, Cannav\u00f2 S (2012) First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary 15(S1):57\u201360","journal-title":"Pituitary"},{"issue":"3","key":"1541_CR92","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11102-013-0494-0","volume":"17","author":"J Komor","year":"2014","unstructured":"Komor J, Reubi JC, Christ ER (2014) Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma. Pituitary 17(3):227\u2013231","journal-title":"Pituitary"},{"issue":"6","key":"1541_CR93","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s11102-013-0540-y","volume":"17","author":"J Maclean","year":"2014","unstructured":"Maclean J, Aldridge M, Bomanji J, Short S, Fersht N (2014) Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma\/carcinoma: variable clinical response in preliminary evaluation. Pituitary 17(6):530\u2013538","journal-title":"Pituitary"},{"issue":"2","key":"1541_CR94","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3171\/2015.6.JNS15363","volume":"125","author":"J Walig\u00f3rska-Stachura","year":"2016","unstructured":"Walig\u00f3rska-Stachura J, Gut P, Sawicka-Gutaj N, Liebert W, Gryczy\u0144ska M, Baszko-B\u0142aszyk D, Blanco-Gangoo AR, Rucha\u0142a M (2016) Growth hormone-secreting Macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog 90 Y-DOTATATE: case report. J Neurosurg 125(2):346\u2013349","journal-title":"J Neurosurg"},{"key":"1541_CR95","unstructured":"Novruzov F, Aliyev JA, Jaunmuktane Z, Bomanji JB, Kayani I (2010) The use of 68 Ga DOTATATE PET\/CT for diagnostic assessment and monitoring of 177 Lu Dotatate therapy in pituitary carcinoma"},{"issue":"3","key":"1541_CR96","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11102-011-0346-8","volume":"15","author":"LD Ortiz","year":"2012","unstructured":"Ortiz LD, Syro LV, Scheithauer BW, Ersen A, Uribe H, Fadul CE, Rotondo F, Horvath E, Kovacs K (2012) Anti-VEGF therapy in pituitary carcinoma. Pituitary 15(3):445\u2013449","journal-title":"Pituitary"},{"key":"1541_CR97","doi-asserted-by":"publisher","unstructured":"Lin AL, Rudneva V, Newton A, Majd NK, Magge R, Sengupta S, Goichot B, Piotrowski A, Gavrilovic I, Cooper O, Rosenblum M, Kaley T, Mellinghoff I, Young RJ, Donoghue MTA, Tabar V, Geer EB (2025) Immune checkpoint inhibitor therapy for aggressive pituitary neuroendocrine tumors. The journal of clinical endocrinology and metabolism, dgaf178. Advance online publication https:\/\/doi.org\/10.1210\/clinem\/dgaf178","DOI":"10.1210\/clinem\/dgaf178"},{"key":"1541_CR98","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27\u201355","journal-title":"Adv Enzyme Regul"},{"issue":"10","key":"1541_CR99","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1210\/jc.2010-0644","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Fran\u00e7ois P, Jouanneau E, Passagia JG, Bernier M, Corn\u00e9lius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95(10):4592\u20134599","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01541-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01541-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01541-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T20:07:02Z","timestamp":1751400422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01541-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1541"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01541-0","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"19 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}